Our latest in @Nature:
Convergence of coronary artery disease genes on endothelial cell programs
https://t.co/5B8tB3IeXI
Incredible work led by Gavin Schnitzler and @kanghelenyihua — a long-standing partnership between our lab and @Dr_RajatGupta
My comments below:
1/
Tweetorial time! We @RecursionPharma mapped consequences of #CRISPR screening of >17K human genes, found a systematic bias confounding all CRISPR screens, traced its molecular cause, and propose a debiasing algorithm.
Extremely proud that our AncestryDNA COVID-19 paper is out in Nature Genetics! So grateful to the entire team of people that got this across the finish line, with special thanks to Kristin Rand, Eurie Hong, Brooke Rhead and Raghav…https://t.co/xNkrsNPGYQ https://t.co/ZYtufpeCZM
Congrats to our @Ancestry collaborators for new findings in @NatureGenet on genetic association with COVID-19 susceptibility & severity. Our collaboration has enabled RGC & Ancestry to share vital learnings with the global scientific community. https://t.co/4ACCAgu1rT
Extremely proud that our AncestryDNA paper is out in @NatureGenet!
This COVID-19 GWAS paper explores the "typical" COVID phenotypes (e.g. hospitalization) + 4 phenotypes that are hard to collect in BioBanks (eg. symptom severity) with self-reported data
https://t.co/td3SagaDca
Online now: Expanded COVID-19 phenotype definitions reveal distinct patterns of genetic association and protective effects (Roberts et al.) https://t.co/4DS15ytq3q
Join us tomorrow for our @lmrl_bio talk at #NeurIPS2021, where we’ll share how our Recursion OS platform and maps of human biology are rapidly accelerating drug discovery. Interested in joining our team? We’re hiring! Apply today: https://t.co/XcuZaiAXG4
Check out our NeurIPS 2021 talk for an in depth look on what we're doing at Recursion to decode biology and radically improve lives. https://t.co/aYnyXLSJzC
@jgschraiber *sigh* The clotting disorder is highly unusual, so it makes sense to figure out why it happens so it can be clinically managed appropriately (e.g. no heparin), but unfortunate that it's gotten so much media attention and will unnecessarily create more hesitancy.
@ShaiCarmi Interesting! I looked at the LD patterns (pic). The arrows show the SNPs we report and the rest are from the paper you linked. One of our signals tags the one from that paper, but our other two signals appear pretty independent.
Very excited to announce that the @Ancestry Science Team just uploaded a new COVID-19 GWAS pre-print with larger sample sizes and an expanded set of 8 phenotype definitions.
https://t.co/I9sm7AQey3
@ShaiCarmi 2) The 3 SNPs in the chr3 locus are not in LD (r2<0.05), so we didn't consider a haplotype analysis, but I will look again at D'. Thanks again!
@ShaiCarmi 1) We considered Bonferroni, but it's a bit conservative & many replication studies use a more relaxed 0.05 even for multiple SNPs. Our major conclusions hold if you apply BF, but we may add a * to show which associations surpass P<0.05/13 in Fig 2. Thanks for the suggestion!
@genandgenes I certainly agree that loci discovered with population controls require increased scrutiny to be sure they are not due to SES confounding, but many of the loci discovered with very large population control GWAS do replicate in follow-up studies that do not use population controls
@MGuru2020@Ancestry We found that our novel phenotype definitions overwhelmingly identified suggestive *protective* associations, but we remain cautious about which of these will replicate as sample sizes grow larger.
We demonstrate the power of leveraging non-clinical case ascertainment and novel phenotype definitions in identifying *protective* genetic associations